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Medicine, Shenzhen University, Shenzhen, ChinaGain-of-function studies often require the tedious cloning of
transgene cDNA into vectors for overexpression beyond the
physiological expression levels. The rapid development of
CRISPR/Cas technology presents promising opportunities to
address these issues. Here, we report a simple, cloning-free
method to induce gene expression at an endogenous locus us-
ing CRISPR/Cas9 activators. Our strategy utilizes synthesized
sgRNA expression cassettes to direct a nuclease-null Cas9 com-
plex fused with transcriptional activators (VP64, p65, and Rta)
for site-speciﬁc induction of endogenous genes. This strategy
allows rapid initiation of gain-of-function studies in the same
day. Using this approach, we tested two CRISPR activation
systems, dSpCas9VPR and dSaCas9VPR, for induction of mul-
tiple genes in human and rat cells. Our results showed that both
CRISPR activators allow efﬁcient induction of six different
neural development genes (CRX, RORB, RAX, OTX2, ASCL1,
and NEUROD1) in human cells, whereas the rat cells exhibit
more variable and less-efﬁcient levels of gene induction, as
observed in three different genes (Ascl1, Neurod1, Nrl). Alto-
gether, this study provides a simple method to efﬁciently
activate endogenous gene expression using CRISPR/Cas9
activators, which can be applied as a rapid workﬂow to initiate
gain-of-function studies for a range of molecular- and cell-
biology disciplines.Received 20 August 2018; accepted 15 November 2018;
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Conventional gene overexpression studies require the need to clone
the transgene cDNA into an expression vector and therefore involve
DNA ligation, bacterial transformation, screening clones, plasmid
puriﬁcation, and quality check to conﬁrm the vector sequences.
This represents a tedious and costly procedure, especially for large-
scale genome-wide overexpression studies. Further to this, the use
of whole-transgene cDNA imposes a challenge for overexpressing
multiple genes simultaneously in cells, due to the large burden of
DNA required to be delivered into the cells.
The emergence of CRISPR/Cas technology has revolutionized the
ﬁeld of molecular biology, providing a promising tool for precise
gene editing with profound implications for development of gene184 Molecular Therapy: Nucleic Acids Vol. 14 March 2019 ª 2018 The
This is an open access article under the CC BY-NC-ND license (httptherapy.1 CRISPR/Cas utilizes an RNA-guided mechanism for site-
speciﬁc DNA cleavage, which has been used to knock in or knock
out genes in vitro2,3 and in vivo.4,5 However, the ﬁrst described Strep-
tococcus pyogenes (Sp)Cas9 is large in size and presents a challenge for
packaging into adeno-associated viruses (AAVs) for therapeutic de-
livery. Subsequently, smaller Cas9 variants have been identiﬁed,
including Staphylococcus aureus (Sa)Cas9,6,7 Neisseria meningitidis
(Nm)Cas9,8 and compylobacter Jejuni (Cj)Cas9,9 which have higher
therapeutic potential due to their smaller sizes. Also, further modiﬁ-
cations of Cas9 have expanded the ability of using CRISPR/Cas
beyond genome editing, including control of gene regulation, epige-
netics, and chromatin imaging.10 For instance, a nuclease-null dead
Cas9 can be fused to transcriptional activators to target the regulatory
region of a gene to induce its expression.11 Importantly, multiple sin-
gle-guide RNAs (sgRNAs) targeting different genes can be utilized to
induce multiplex gene expression. Since only a short sgRNA is needed
to induce expression of a single gene, rather than a whole-transgene
cDNA copy, the CRISPR activation approach can potentially reduce
the number of viral vectors needed for overexpressing multiple genes.
Another advantage of CRISPR activation is it activates gene expres-
sion directly at endogenous locus with high speciﬁcity, which allows
for expression of splice variants as well as endogenous gene regulation
via UTR regions.12,13
Several reports have previously utilized a cloning-free CRISPR
approach to knock in or knock out genes. In ﬁssion yeasts, Zhang
et al.14 showed that the gap-repair mechanism can be used to
assemble PCR-ampliﬁed sgRNA fragments and linear Cas9 plasmids
together. In mammalian cells, Arbab et al.15 have reported a self-clon-
ing CRISPR/Cas9 approach by using palindromic sgRNA, either in
expression cassette or short DNA sequences, to allow homologous
recombination in target cells to yield a functional site-speciﬁc sgRNAAuthors.
://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1. Information of sgRNAs Used for SpCas9
Species Name TSS Distance Strand Sequence PAM On-Target Score
Rat Ascl1 sgRNA 1 183 bp + 50-ACGCACTGCAACAACAAACC-30 CGG 46.1
Ascl1 sgRNA 2 351 bp  50-TCCTAGGTAGAAAGTCTGGA-30 GGG 73.4
Neurod1 sgRNA 1 258 bp + 50-TGCGGGTAAAAACAGGTCCG-30 CGG 56.1
Neurod1 sgRNA 2 164 bp + 50-ATACAAATAGGCAGGTCACG-30 TGG 84.1
Nrl sgRNA 1 573 bp  50-CTTTACCTCTCAAAGCCTTC-30 AGG 27.5
Nrl sgRNA 2 764 bp + 50-CCATCTGCTTAGACTCACCA-30 TGG 77.8
Human ASCL1 sgRNA 1 181 bp + 50-CGGGAGAAAGGAACGGGAGG-30 GGG 30.9
NEUROD1 sgRNA 1 33 bp + 50-AGGGGAGCGGTTGTCGGAGG-30 AGG 30.9
RAX sgRNA 99 bp + 50-GAGGGAGGGGCCGAGAGAAG-30 GGG 44.0
OTX2 sgRNA 170 bp + 50-AGATTGTAATTGCTTTCTTC-30 GGG 35.2
CRX sgRNA 114 bp  50-AGGGAGGCCCCAGCTCCTGC-30 CGG 51.6
RORB sgRNA 172 bp + 50-CCCGGCCACCTCGGACTCCC-30 TGG 41.8
Mouse Nkx2.5 sgRNA 171 bp + 50-GTATTTTCTTTGAGTGTGTC-30 TGG 36.1
On-target score is an optimized score for 20-bp sgRNA based on Doench et al.28. Scores range from 0–100. TSS, transcription start site.
www.moleculartherapy.orgplasmid. The authors also showed that co-transfection of the Cas9
expression plasmids and sgRNA expression cassettes synthesized as
short 500-bp oligonucleotides allow efﬁcient knockout of target
gene in mouse embryonic stem cells. Others have described the use
of CRISPR ribonucleoprotein complexes for generation of knockin
mice,16,17 as well as gene editing in mammalian cells in vitro delivered
through various methods, such as transfection by cationic lipids,
nanoparticles, or cell-penetrating peptides.18–22 However, a cloning-
free approach has not been systematically reviewed for gene activa-
tion or repression using CRISPR/Cas9.
Here, we present a simple and rapid method to use CRISPR/Cas for
gene activation. Our method utilizes commercially synthesized
sgRNA expression cassettes, which bypass the need for molecular
cloning of site-speciﬁc sgRNA plasmids. In this study, we compare
the use of synthesized sgRNA expression cassettes with two
CRISPR/Cas activators, dSpCas9VPR and dSaCas9VPR, to induce
gene expression in human and rat cells. Our strategy vastly simpliﬁes
the initiation of gain-of-function studies and as such has implications
across many disciplines in cell biology.
RESULTS
To utilize CRISPR/Cas to activate endogenous genes in mammalian
cells, we ﬁrst tested the dSpCas9VPR system.23 This system utilizes
a nuclease-null dead SpCas9 (dSpCas9) coupled with transcription
factor activation domains VP64, p65, and Rta (VPR). The sgRNAs
were designed using the synergistic activation mediator (SAM)
sgRNA design tool. For gene activation, we chose six human genes
that encoded for transcription factors that regulate neural and retinal
development: RAX, OTX2, RORB, CRX, ASCL1, and NEUROD1
(Table 1). We synthesized sgRNA expression cassettes as linear oligo-
nucleotide fragments containing an upstream U6 promoter, the
sgRNA, and the corresponding sgRNA scaffold (Figure S1). The
sgRNA expression cassettes and the dSpCas9VPR plasmids wereco-transfected into HEK293A cells. By day 3 post-transfection, we
can detect robust gene activation in HEK293A cells using
dSpCas9VPR, with upregulation of OTX2 (375-fold increase; Fig-
ure 1A), RAX (13-fold increase; Figure 1B), RORB (110-fold in-
crease; Figure 1C), and CRX (35-fold increase; Figure 1D). Simi-
larly, the dSpCas9VPR system is also efﬁcient in gene activation of
ASCL1 and NEUROD1, with 70-fold increase and 585-fold in-
crease, respectively (Figure 1E). Immunocytochemistry analysis also
conﬁrmed efﬁcient expression of ASCL1 protein in HEK293A
following dSpCas9VPR gene activation (Figure 1F).
To determine the kinetics of the gene activation, we performed a
time-course experiment following ASCL1 gene activation. Our results
showed that dSpCas9VPR upregulated ASCL1 expression levels after
2 days and gradually decreased after 3 days, with persistent upregu-
lated levels up to 6 days post-transfection (Figure S3). These results
showed that dSpCas9VPR resulted in maximal gene activation level
after 2–3 days following transfection.
Subsequently, we tested the feasibility of using dSpCas9VPR for
multiplex gene activation. We co-transfected sgRNAs for ASCL1
and NEUROD1 into HEK293A cells. Notably, both genes can be up-
regulated simultaneously and efﬁciently using the dSpCas9VPR, with
13-fold induction of ASCL1 expression and485-fold induction of
NEUROD1 expression (Figure 1E). However, multiplexing resulted in
a lower level of gene induction compared to using single sgRNA, an
effect more prominent in induction of ASCL1 (Figure 1E). Taken
together, our results demonstrated that dSpCas9VPR can be used to
efﬁciently activate gene expression in human cells.
Furthermore, we assessed the feasibility of using dSpCas9VPR
for gene activation in rat cells. As the SAM sgRNA design tool
does not support design for the rat genome, we utilized the gene-acti-
vator sgRNA design tool in Benchling (Table 1). We analyzedMolecular Therapy: Nucleic Acids Vol. 14 March 2019 185
Figure 1. Efficient Gene Activation Using
dSpCas9VPR in HEK293A Cells
qPCR analysis of gene activation for (A)OTX2, (B) RAX, (C)
RORB, (D) CRX, (E) ASCL1, NEUROD1, or multiplex in-
duction of ASCL1 and NEUROD1. Results are displayed
as the mean of three independent biological repeats ±
SEM. (F) Immunocytochemistry results showed upregu-
lated protein expression of ASCL1 (green) in HEK293A
following gene activation with dSpCas9VPR. Scale bars,
100 mm.
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Figure 2. Assessment of Multiple sgRNAs for dSpCas9VPR to Induce Gene Activation in Rat Mu¨ller Glial Cell rMC1
qPCR analysis of gene activation using two sgRNAs, respectively, for (A) Ascl1, (B) Neurod1, and (C) Nrl. Results are displayed as the mean of four independent biological
repeats ± SEM.
www.moleculartherapy.orgdSpCas9VPR-mediated activation of three genes, Ascl1,Neurod1, and
Nrl, in a rat Müller glial cell line rMC1, which can be transfected efﬁ-
ciently (Figure S5). Our results showed that Ascl1 can be activated to
modest levels using two sgRNAs, resulting in an3- and2-fold in-
crease, respectively (Figure 2A). Similarly, two sgRNAs were tested
for Neurod1 gene activation. While one sgRNA resulted in a modest
increase in Neurod1 expression levels (3-fold increase), another
sgRNA failed to activate Neurod1 (Figure 2B). For Nrl, the two de-
signed sgRNAs resulted in an 3- and 1.6-fold induction in gene
expression, respectively (Figure 2C). We also tested gene activation
with dSpCas9VPR in another rat ﬁbroblast cell line R12. However,
we did not observe signiﬁcant gene activation in Ascl1, Neurod1,
nor Nrl (Figure S4). This is unlikely due to problems with transfec-
tion, as R12 can be efﬁciently transfected in this context (Figure S5).
Moreover, we showed that the dSpCas9VPR can efﬁciently activate
gene expression in mouse embryonic ﬁbroblasts (19-fold increase
in Nkx2.5; Figure S6), suggesting that the inefﬁcient CRISPR activa-
tion seen is speciﬁc to rat cells and not other rodent cells. Collectively,
these results demonstrated that dSpCas9VPR can be used to activate
genes in rat cells, albeit only limited to modest levels of upregulation
in certain rat cells and is not as efﬁcient as in human cells.
Next, we assessed the efﬁciency of gene activation using another
CRISPR/Cas activation system, dSaCas9VPR, which utilizes a
nuclease-null SaCas9 coupled with VPR. Notably, the dSaCas9VPR
is much smaller in size than dSpCas9VPR, which has important impli-
cations for packaging into viral vectors for gene therapy. We designed
sgRNAs using Benchling for both human and rat genes and selected
two to three sgRNAs against each gene for evaluation (Table 2). The
sgRNA expression cassette for dSaCas9VPR contained a 50 Myc
tag, upstream U6 promoter, sgRNA, sgRNA scaffold, and a 30 HA
tag (Figure S2). In HEK293A cells, we showed that dSaCas9VPR can
activate the expression levels of endogenous ASCL1 efﬁciently
(760-fold increase; Figure 3A). Also, we detected upregulation of
the ASCL1 protein levels following dSaCas9VPR gene activation (Fig-
ure 3B). However, dSaCas9VPR exhibited variable efﬁciency in gene
activation in rMC1 cells (Figure 4), a result similar to those observed
in dSpCas9VPR. Two sgRNAs were tested for activation of Ascl1 orNeurod1, with one sgRNA inducingmodest levels of gene upregulation
and the other failing to do so (Ascl1, 2.6, 1 fold changes; Neurod1,
2.8, 1 fold changes; Figures 4A and 4B). However, for Nrl activa-
tion, all three sgRNAs tested failed to upregulate Nrl expression levels
(Figure 4C). In summary, we showed that dSaCas9VPR can be used to
efﬁciently activate gene expression in human cells; however, its effect
in rat cells is variable and remained inefﬁcient.
DISCUSSION
A key limiting factor in the conventional design of overexpression
studies is the requirement of tedious plasmid construction for each
transgene, which involves molecular cloning steps that take more
than 1 week. Here, we present a simpliﬁed method for gene activation
using CRISPR/Cas9 activators in mammalian cells that is feasible in
1 day. Notably, our strategy to transfect sgRNA as a synthesized linear
oligonucleotide fragment with U6 promoter allows sgRNA expression
in the cells and eliminates the need to clone sgRNA into a designated
vector prior to transfection. Our strategy provides a rapid way to
initiate gene-overexpression studies using the CRISPR activation
system.
This study compared two CRISPR activation systems, dSpCas9VPR
and dSaCas9VPR, in human and rat cells. Our results demonstrated
that both dSpCas9VPR and dSaCas9VPR can efﬁciently induce gene
expression in human cells. We showed the use of dSpCas9VPR for
multiplex activation of two genes in human cells, as well as its high
efﬁciency for gene activation in mouse cells. Furthermore, in rat cells
we have assessed activation of three genes using six sgRNAs for
dSpCas9VPR and seven sgRNAs for dSaCas9VPR in two different
rat cell lines. However, our results showed only modest levels and,
in some cases, negligible levels of gene activation in rat Müller glial
cells and ﬁbroblasts. This is unlikely due to issues with transfection
efﬁciency, as both rat cell types can be efﬁciently transfected with
robust GFP expression. We speculate that this could be due to inad-
equate support of the current sgRNA design algorithm for the rat
genome. For instance, many of the sgRNAs used for rat genes have
high ranking of on-target scores (Table 2), but they are mostly inefﬁ-
cient in inducing expression of rat genes using the CRISPR activationMolecular Therapy: Nucleic Acids Vol. 14 March 2019 187
Table 2. Information of sgRNAs Used for SaCas9
Species Name TSS Distance Strand Sequence PAM On-Target Score On-Target Score Ranking
Rat Ascl1 sgRNA 1 180 bp + 50-GCACTGCAACAACAAACCCGG-30 CTGAAT 70.9 1
Ascl1 sgRNA 2 223 bp  50-TGGCGCGTGCCGGACTCCCGG-30 CTGAAT 64.2 5
Neurod1 sgRNA 1 258 bp + 50-CTGCGGGTAAAAACAGGTCCG-30 CGGAGT 56.1 2
Neurod1 sgRNA 2 205 bp + 50-TTCTTCTGGCCACAAAGGGGC-30 CGGAAT 38.5 5
Nrl sgRNA 1 575 bp  50-TTTACCTCTCAAAGCCTTCAG-30 GAGAGT 79.3 1
Nrl sgRNA 2 145 bp + 50-TTCAGGGCTGCTTCATTACTC-30 CGGAAT 45.1 9
Nrl sgRNA 3 760 bp  50-TTTAACTTAGCACCTGCCATG-30 GTGAGT 72.7 2
Human ASCL1 sgRNA 239 bp + 50-GCACTGCAACAACAAACCCAG-30 CTGAAT 74.2 2
On-target score is an optimized score for 20-bp sgRNA based on Doench et al.28. The on-target scores are ranked for sgRNAs targeting 2,000-bp upstream of transcription start site of
genes. Scores range from 0–100. TSS, Transcription start site.
Molecular Therapy: Nucleic Acidssystems. This highlights the need to improve the design and accuracy
of predicting functional sgRNAs for the rat genome. Furthermore, it
is also possible that the differences in gene activation we observed are
due to variations in chromatic state and accessibility in different rat
and human cells. Therefore, alternative CRISPR activation systems
may be more effective at enhancing gene activation in rat cells. In
addition to the dCas9-VPR system from the Church laboratory, other
CRISPR activation systems have been described, such as the SAM sys-
tem, the SunTag activator system, and dCas9-VP128 system.24–26
These alternative CRISPR activation systems utilize distinct tran-
scriptional activators to enhance gene activity. Chavez et al.11 under-
took a comprehensive head-to-head comparison of various CRISPR
activation systems and found that different systems showed varying
activities at different gene loci as well as in different cell types tested.
Notably, the simpliﬁed method for gene activation described here can
also be adopted for other CRISPR systems for gene editing or repres-
sion, which allows rapid testing of effective sgRNA sequences that can
be selected for further experiments in different delivery systems. Also,
our sgRNA expression cassette design can be applied to different Cas9
activator systems, since the same sgRNA design can be used for
different Cas9 activator systems (such as SpCas9VPR, SpCas9-Sun-
tag, SpCas9-VP64).
A potential challenge of using CRISPR/Cas systems is that not all
sgRNAs are efﬁcient in Cas9 targeting; thus, multiple sgRNAs are
often screened to identify the functional sgRNAs. In our experience,
the sgRNA design tools for predicting functional sgRNAs are gener-
ally very accurate for human cells. For dSpCas9VPR, the ﬁrst sgRNA
designed is functional for gene activation in 13 out of 15 genes tested
(87%; Table S1). Similarly, although we only tested gene activation
for a single gene using dSaCas9VPR, the ﬁrst sgRNA designed is
highly efﬁcient for gene activation (Table S1). Therefore, we recom-
mend designing two sgRNAs within 300 bp upstream of the tran-
scription start site to be tested for gene activation in human cells. It
should be noted that sgRNAs that target different proximities of the
transcriptional start site can result in different efﬁciencies of gene acti-
vation,18 and this can be further optimized for individual target genes
of interest. Additionally, it is also possible to combine several sgRNAs188 Molecular Therapy: Nucleic Acids Vol. 14 March 2019targeting different promoter regions to improve the levels of gene
activation using CRISPRa.
In summary, this study outlines a simple and robust workﬂow to efﬁ-
ciently activate endogenous gene expression in mammalian cells us-
ing CRISPR/Cas activators, which can be applied as a rapid workﬂow




This study was approved by the Institutional Biosafety Committee at
Monash University (#10969) in compliance with the regulations by
the Ofﬁce of the Gene Technology Regulator in Australia.
sgRNA Design and Preparation of Expression Cassette
For SpCas9, sgRNAs with NGG protospacer adjacent motifs (PAMs)
were designed using the SAM sgRNA design tool (http://sam.
genome-engineering.org/database/) for human genes and Benchling
(https://benchling.com/) for rat genes. The SpCas9 sgRNA expression
cassette contains an upstreamU6 promoter, sgRNA, and sgRNA scaf-
fold with stem extension and stem loop (Figure S1).
For SaCas9, sgRNAs with NNGRRT PAMs were designed using
Benchling (https://benchling.com/). Predicted sgRNAs with long
stretches of repeating nucleotides are excluded from selection. The
SaCas9 sgRNA expression cassette contains a Myc tag, U6 promoter,
sgRNA, sgRNA scaffold, and HA tag (Figure S2).
Both SpCas9 and SaCas9 sgRNA expression cassettes (<500 bp) were
synthesized as gBLOCK gene fragments (Integrated DNA Technolo-
gies). The sgRNA expression cassettes were ampliﬁed by PCR using
the following primers: SpCas9 forward primer, 50-TGAGTAT
TACGGCATGTGAGGGC-30; SpCas9 reverse primer, 50-TCAATG
TATCTTATCATGTCTGCTCGA-30; SaCas9 forward primer, 50-GA
ACAAAAACTCATCTCAGAAGAGGATCTG-30; SaCas9 reverse
primer, 50-TACCCATACGATGTTCCAGATTACGCT-30. PCR was
performed using KOD Hot Start DNA polymerase (Merck Millipore)
with the following thermal proﬁle: 95C for 2 min; 30 cycles of 95C
Figure 3. Efficient Gene Activation Using
dSaCas9VPR in HEK293A Cells
(A) qPCR analysis of gene activation for ASCL1 in
HEK293A cells. Results are displayed as mean of three
independent biological repeats ± SEM. (B) Immunocyto-
chemistry results showed upregulated protein expression
of ASCL1 (green) in HEK293A following gene activation
with dSaCas9VPR. Scale bars, 100 mm.
www.moleculartherapy.orgfor 20 s, 66C (SpCas9 sgRNA) or 64C (SaCas9 sgRNA) for 10 s,
70C for 8 s; 70C for 5 min. The PCR amplicons were separated
by gel electrophoresis, and the sgRNA expression cassettes were ex-
tracted using the Wizard SV gel and PCR cleanup kit (Promega).
The ampliﬁed sgRNA expression cassettes were checked with Nano-
drop to conﬁrm good DNA quality.
Cell Culture
Rat Müller glial cells rMC1, rat ﬁbroblasts R12, mouse embryonic
ﬁbroblasts, and HEK293A cells were maintained in DMEM high-
glucose media supplemented with 10% fetal calf serum, 2 mM
L-glutamine, and 0.5% penicillin/streptomycin (all from Thermo
Fisher). All cells were passaged using 0.25% trypsin before the culture
become conﬂuent andmaintained in incubators at 37Cwith 5% CO2
level.
Transfection Efficiency Assay
rMC1 and R12 cells were transfected with the pmaxGFP construct
(Lonza) using Lipofectamine 3000 overnight, following the manufac-
turer’s instruction. GFP expression is determined 1 day after transfec-
tion using a ﬂuorescence microscope (Olympus CKX53).
Gene Activation Using CRISPR/Cas Activation
dSaCas9-VPR and dSpCas9-VPR plasmids were gifts from George
Church (Addgene #68495 and #63798, respectively). rMC1, R12,
mouse embryonic ﬁbroblasts and HEK293A cells were transfected us-
ing Lipofectamine 3000. In brief, cells were plated down on a 12-wellFigure 4. Comparison of Multiple sgRNAs to Induce Gene Activation in Rat Mu¨
qPCR analysis of gene activation for (A) Ascl1 using two sgRNAs, (B)Neurod1 using two
to five independent biological repeats ± SEM.plate at day 0 (6  104/well). At day 1, the cells were transfected with
360 ng sgRNA expression cassettes and 800 ng dSaCas9-VPR or
dSpCas9-VPR plasmids using Lipofectamine 3000 overnight. In
some experiments, the cells and DNA were upscale proportionally
to obtain more RNA. Mock control (no DNA transfected) was uti-
lized as a negative control. At day 4, the samples were harvested for
RNA to assess gene expression levels or ﬁxed for immunocytochem-
istry analysis. In some experiments, RNA was harvested at different
time points (days 2, 3, 4, 5, and 6) to determine kinetics of CRISPR
gene activation.
qPCR Analysis
Total RNA was extracted using the RNeasy kit (QIAGEN) or the Illus-
tra RNAspin kit (GE Healthcare) followed by DNase treatment. For
mouse embryonic ﬁbroblasts, RNA was extracted from cells using
TriReagent (Thermo Fisher) followed by RNA precipitation with chlo-
roform and isopropanol (Sigma-Aldrich). cDNA synthesis was per-
formed using the High Capacity cDNA Reverse Transcription Kit
(Thermo Fisher) following the manufacturer’s instructions. Taqman
gene-expression assay (Thermo Fisher) was performed using the Taq-
man Fast Advanced Master Mix with the following probes: human
RAX (Hs00429459_m1), human OTX2 (Hs00222238_m1), human
ASCL1 (Hs00269932_m1), human NEUROD1 (Hs00159598_m1),
human CRX (Hs00230899_m1), human RORB (Hs00199445_m1),
human ACTB (Hs99999903_m1), rat Ascl1 (Rn00574345_m1), rat
Neurod1 (Rn00824571_s1), rat Nrl (Rn01481925_m1), rat Gapdh
(Rn01775763_g1), mouse Nkx2.5 (Mm00657783_m1), and mouseller Glial Cell rMC1 Using dSaCas9VPR
sgRNAs, and (C)Nrl using three sgRNAs. Results are displayed as the mean of three
Molecular Therapy: Nucleic Acids Vol. 14 March 2019 189
Molecular Therapy: Nucleic AcidsGapdh (Mm99999915_g1). qPCR was processed using the ABI Step
One Plus system, the ABI 7500 system, or the QuantStudio 6 Flex
Real-Time PCR system (Applied Biosystems). The delta delta Ct
method was used to calculate relative gene expression compared to
control. Gene expression for each transfected condition was normal-
ized to its corresponding mock control. The housekeeping genes
ACTB or Gapdh were used for normalizing gene expression in human
and rat cells, respectively.
Immunocytochemistry Analysis
Standard immunocytochemistry procedures were carried out as pre-
viously described.27 In brief, samples were ﬁxed inmethanol, followed
by blocking and permeabilization (0.1% Tween 20). Subsequently, the
samples were immunostained with antibodies against ASCL1 (Ab-
cam, #ab74065, 5 mg/mL), the appropriate Alexa Fluor 488 secondary
antibodies (Abcam), and nuclear counterstain with DAPI (Sigma).
Samples were imaged using a Nikon Eclipse TE2000-U ﬂuorescent
microscope.
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